Cargando…

Glioblastoma—a moving target

The slow development of effective treatment of glioblastoma is contrasted by the rapidly advancing research on the molecular mechanisms underlying the disease. Amplification and overexpression of receptor tyrosine kinases, particularly EGFR and PDGFRA, are complemented by mutations in the PI3K, RB1,...

Descripción completa

Detalles Bibliográficos
Autor principal: Westermark, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339557/
https://www.ncbi.nlm.nih.gov/pubmed/22512247
http://dx.doi.org/10.3109/03009734.2012.676574
_version_ 1782231377943461888
author Westermark, Bengt
author_facet Westermark, Bengt
author_sort Westermark, Bengt
collection PubMed
description The slow development of effective treatment of glioblastoma is contrasted by the rapidly advancing research on the molecular mechanisms underlying the disease. Amplification and overexpression of receptor tyrosine kinases, particularly EGFR and PDGFRA, are complemented by mutations in the PI3K, RB1, and p53 signaling pathways. In addition to finding effective means to target these pathways, we may take advantage of the recent understanding of the hierarchical structure of tumor cell populations, where the progressive expansion of the tumor relies on a minor subpopulation of glioma stem cells, or glioma-initiating cells. Finding ways to reprogram these cells and block their self-renewal is one of the most important topics for future research.
format Online
Article
Text
id pubmed-3339557
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-33395572012-05-24 Glioblastoma—a moving target Westermark, Bengt Ups J Med Sci Review Article The slow development of effective treatment of glioblastoma is contrasted by the rapidly advancing research on the molecular mechanisms underlying the disease. Amplification and overexpression of receptor tyrosine kinases, particularly EGFR and PDGFRA, are complemented by mutations in the PI3K, RB1, and p53 signaling pathways. In addition to finding effective means to target these pathways, we may take advantage of the recent understanding of the hierarchical structure of tumor cell populations, where the progressive expansion of the tumor relies on a minor subpopulation of glioma stem cells, or glioma-initiating cells. Finding ways to reprogram these cells and block their self-renewal is one of the most important topics for future research. Informa Healthcare 2012-05 2012-04-19 /pmc/articles/PMC3339557/ /pubmed/22512247 http://dx.doi.org/10.3109/03009734.2012.676574 Text en © Informa Healthcare http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.
spellingShingle Review Article
Westermark, Bengt
Glioblastoma—a moving target
title Glioblastoma—a moving target
title_full Glioblastoma—a moving target
title_fullStr Glioblastoma—a moving target
title_full_unstemmed Glioblastoma—a moving target
title_short Glioblastoma—a moving target
title_sort glioblastoma—a moving target
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339557/
https://www.ncbi.nlm.nih.gov/pubmed/22512247
http://dx.doi.org/10.3109/03009734.2012.676574
work_keys_str_mv AT westermarkbengt glioblastomaamovingtarget